Empagliflozin: a new strategy for nephroprotection in diabetes
Empagliflozin, an inhibitor of sodiumglucose symporter type 2 (SGLT2), is a new class of antidiabetic agents with numerous pleiotropic effects. The review summarises data on the influence of empagliflozin on the structural and functional changes in the kidneys of the models of diabetes mellitus (DM)...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2017-05-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://dia-endojournals.ru/dia/article/viewFile/8005/6362 |